JP2024514703A5 - - Google Patents
Info
- Publication number
- JP2024514703A5 JP2024514703A5 JP2023564639A JP2023564639A JP2024514703A5 JP 2024514703 A5 JP2024514703 A5 JP 2024514703A5 JP 2023564639 A JP2023564639 A JP 2023564639A JP 2023564639 A JP2023564639 A JP 2023564639A JP 2024514703 A5 JP2024514703 A5 JP 2024514703A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- fluoroalkyl
- general formula
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110439238 | 2021-04-22 | ||
| CN202110439238.4 | 2021-04-22 | ||
| PCT/CN2022/087652 WO2022222921A1 (zh) | 2021-04-22 | 2022-04-19 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514703A JP2024514703A (ja) | 2024-04-02 |
| JP2024514703A5 true JP2024514703A5 (cg-RX-API-DMAC7.html) | 2025-04-28 |
Family
ID=83721971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564639A Pending JP2024514703A (ja) | 2021-04-22 | 2022-04-19 | ピペラジン構造を有するparp阻害剤、その調製方法およびその医薬的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336624A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4328224A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514703A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230175225A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117279916B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022261011A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021383A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3213029A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012361A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022222921A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| CN116867783B (zh) * | 2021-04-23 | 2026-08-07 | 康百达(四川)生物医药科技有限公司 | 吡啶衍生物及其在医药上的应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药(杭州)有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023051812A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| TWI876212B (zh) | 2021-10-01 | 2025-03-11 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
| CN118434725B (zh) * | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| PT4497438T (pt) | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| AU2023275808A1 (en) * | 2022-05-25 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| CN117946074A (zh) * | 2022-10-20 | 2024-04-30 | 上海海和药物研究开发股份有限公司 | 具有parp1抑制活性的化合物及其用途 |
| CN120092010A (zh) * | 2022-11-02 | 2025-06-03 | 轩竹生物科技股份有限公司 | 多环类聚(adp核糖)聚合酶选择性抑制剂 |
| AU2023412594A1 (en) * | 2022-12-23 | 2025-07-10 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| WO2024213111A1 (zh) * | 2023-04-14 | 2024-10-17 | 微境生物医药科技(上海)有限公司 | Parp抑制剂、其制备方法及医药用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009053373A1 (en) * | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| EP2389379A1 (en) * | 2009-01-23 | 2011-11-30 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| EP2415767B1 (en) * | 2009-03-27 | 2014-09-03 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) Polymerase (PARP) Inhibitors |
| PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
| PT3562822T (pt) * | 2016-12-30 | 2021-06-02 | Mitobridge Inc | Inibidores de poli-adp ribose polimerase (parp) |
| TWI837403B (zh) * | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| CN117177972A (zh) * | 2021-04-19 | 2023-12-05 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CN116710433B (zh) * | 2021-04-23 | 2026-05-05 | 康百达(四川)生物医药科技有限公司 | 一种选择性parp1抑制剂及其应用 |
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
-
2022
- 2022-04-19 WO PCT/CN2022/087652 patent/WO2022222921A1/zh not_active Ceased
- 2022-04-19 CA CA3213029A patent/CA3213029A1/en active Pending
- 2022-04-19 JP JP2023564639A patent/JP2024514703A/ja active Pending
- 2022-04-19 US US18/281,855 patent/US20240336624A1/en active Pending
- 2022-04-19 KR KR1020237038365A patent/KR20230175225A/ko active Pending
- 2022-04-19 MX MX2023012361A patent/MX2023012361A/es unknown
- 2022-04-19 CN CN202280029738.3A patent/CN117279916B/zh active Active
- 2022-04-19 AU AU2022261011A patent/AU2022261011A1/en active Pending
- 2022-04-19 BR BR112023021383A patent/BR112023021383A2/pt unknown
- 2022-04-19 EP EP22791028.8A patent/EP4328224A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230239A1 (es) | Derivado de arilamida con actividad antitumoral | |
| JP2022500425A5 (cg-RX-API-DMAC7.html) | ||
| EA202092169A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2 | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| JP2021513547A5 (cg-RX-API-DMAC7.html) | ||
| AR035959A1 (es) | Compuestos agonistas en el receptor cb2, uso de estos compuestos para la manufactura de un medicamento para utilizar en la terapia del dolor, composicion farmaceutica, y metodo de reduccion | |
| AR013879A1 (es) | Compuesto parasiticida derivado pirazol, formulaciones veterinarias o agricolas y composiciones farmaceuticas que lo contienen, el uso de dicho compuesto para la manufactura de medicamentos, compuestos utiles y procedimiento para la fabricacion de dicho compuesto | |
| JP2005505618A5 (cg-RX-API-DMAC7.html) | ||
| JP2023552610A5 (cg-RX-API-DMAC7.html) | ||
| JP2020505440A5 (cg-RX-API-DMAC7.html) | ||
| RU2010107169A (ru) | Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого | |
| JP2020503341A5 (cg-RX-API-DMAC7.html) | ||
| RU2010115337A (ru) | Трициклические гетероциклические производные | |
| JP2018510202A5 (cg-RX-API-DMAC7.html) | ||
| RU2017133660A (ru) | Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций | |
| JP2021513543A5 (cg-RX-API-DMAC7.html) | ||
| PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
| CR20230218A (es) | Nuevos derivados de indazol acetileno | |
| PY2167570A (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| FI934045A0 (fi) | Pyridin- och imidazolderivat foer kardiovaskulaera sjukdomar | |
| JP2021503451A5 (cg-RX-API-DMAC7.html) | ||
| AR128917A1 (es) | Inhibidores de malt-1 de tiazolo[5,4-b]piridina | |
| RU2023128311A (ru) | Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение | |
| JPWO2021132311A5 (cg-RX-API-DMAC7.html) | ||
| ME00057B (me) | Novi derivati morfolina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže |